DAsatinib DIscontinuation for 1st-Line treatment with Chronic Myelogenous Leukemia-Chronic Phase with One Year Complete Molecular Remission

Next Previous
Trial Profile

DAsatinib DIscontinuation for 1st-Line treatment with Chronic Myelogenous Leukemia-Chronic Phase with One Year Complete Molecular Remission

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2013

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms DADI; IMIDAS-4

    • Most Recent Events

    • 07 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top